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Abstract
Background: Non-Islet Cell Tumor Hypoglycemia (NICTH) is a rare paraneoplastic cause of hypoglycemia arising
from excess tumor production of insulin-like growth factor. The objective of this report is to describe an unusual
case of Extragastrointestinal Stromal Tumor (EGIST) associated NICTH.
Case presentation: A 64 year-old African female was brought to the emergency room with a 1-month history of
recurrent syncope, weight loss, and abdominal bloating. Serum blood glucose was discovered to 39 mg/dL, when
insulin, proinsulin, and C-peptide were suppressed. Computed tomography scan revealed a diffuse extraintestinal
metastatic disease process, and a biopsy confirmed the diagnosis of an Extragastrointestinal Stromal Tumor (EGIST).
IGF-I and II levels were 27 ng/ml and 262 ng/ml respectively, and the ratio of IGF-II to IGF-I was calculated as 9.7:1,
suggestive of IGF-II-mediated NICTH. Acutely, the patient’s hypoglycemia resolved with dextrose and glucagon
infusion. Long-term euglycemia was achieved with prednisone and imatinib therapy.
Conclusions: NICTH should be considered when hypoglycemia occurs in the setting of low serum insulin levels.
Whereas definitive treatment of EGIST involves surgical resection, immunotherapy with tyrosine kinase inhibitors
and corticosteroids have been shown to alleviate hypoglycemia in cases where surgery is delayed or not feasible.
Keywords: Tumor induced hypoglycemia, Extragastrointestinal stromal tumor (GIST), Non-islet cell tumor
hypoglycemia
Background
Tumor induced hypoglycemia can be divided into two
broad categories. The first involves insulin hypersecretion
from pancreatic islet cell insulinomas. The second, known
as Non-Islet Cell Tumor Hypoglycemia (NICTH), is from
paraneoplastic production of insulin-like growth factor
from a tumor, leading to unrestrained glucose uptake at
peripheral tissues [1, 2]. The first description of NICTH
dates back to 1929 and involved a patient with metastatic
hepatocellular carcinoma. Post-mortem examination of
the pancreas was normal. Furthermore, analysis of the
tumor failed to reveal the presence of insulin, thus leading
to the conclusion that the hypoglycemia was non-insulin
mediated [3]. Since this original description, a variety of
tumors have been shown to exhibit NICTH. These pri-
marily include tumors of mesenchymal and epithelial ori-
gin with hepatocellular carcinomas being among the most
frequently implicated.
Gastrointestinal Stromal Tumor (GIST) is the most com-
mon mesenchymal tumor arising within the gastrointestinal
(GI) tract. These tumors express the phenotype of the
Interstitial Cells of Cajal or related stem cell-like precursors
and are associated with somatic mutations of the tyrosine
kinase receptors c-kit (CD117) and platelet-derived growth
factor-α (PDGFR-α) [4–6]. Over the last decade, a handful
of case reports have described an association between GIST
and NICTH [5]. In extremely rare cases, GIST can arise
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primarily outside the GI tract, where it is termed Extragas-
trointestinal Stromal Tumor (EGIST) [6, 7]. Representing
less than 10% of all stromal tumors, EGISTs share the same
histological features, immunophenotype, and biological be-
havior as GISTs. Most EGISTs originate in the lesser or
greater omentum, the mesentery, or less commonly in the
retroperitoneum, with very few cases reported of tumors
arising from the abdominal wall itself [6, 8]. While some
sources suggest that EGISTs represent peritoneal metasta-
ses of undiagnosed GISTs or GISTs that may have detached
from the intestinal wall during extensive extramural
growth, others consider them to be primary tumors arising
from multipotent mesenchymal stems cells of the extra-
intestinal tissue [6, 8, 9]. Surgery remains a mainstay for lo-
calized GIST/EGIST. However, immunotherapy with tyro-
sine kinase inhibitors (TKI), especially imatinib, has
emerged as a promising neoadjuvant or alternative therapy.
Here, we describe the case of a patient presenting with
a rare abdominopelvic EGIST tumor and recurrent epi-
sodes of severe symptomatic hypoglycemia. To the best
of our knowledge, this is the first reported case linking
EGIST and NICTH.
Case Presentation
A 64 year-old African female was brought to the emergency
room in January 2016 with a chief complaint of recurrent
syncope. Her serum blood glucose on arrival was 39 mg/
dL. A detailed review of systems was notable for non-
specific abdominal bloating and distension and a 50 lb
weight loss over the preceding year. Vital signs on presenta-
tion were within normal limits; physical exam revealed a
firm palpable right lower quadrant mass. Her past medical
history revealed a history of pelvic EGIST that had been di-
agnosed in March 2010 at an outside facility. A computed
tomography (CT) scan at that time demonstrated a large
pelvic mass involving the right ovary, the mesovarian, and
the mesometrium. Pathological analysis of the tumor re-
vealed diffuse staining for c-Kit, CD-34, and the smooth
muscle marker caldesmon, while stains for pancytokeratin,
S-100, Human Melanoma Black (HMB-45), Melan-A,
actin, myogenin and desmin were all negative. The mitotic
index was noted to be high at 28/50 high power fields, and
tumor necrosis was noted. Following a debulking proced-
ure, all intestinal specimens were found to tumor-free.
Hence, the diagnosis of a primary EGIST was made. Post-
operatively, she was started on immunotherapy with the
TKI, imatinib. Since that time, the patient missed most of
her follow-up appointments. During the current admission,
she reported discontinuation of imatinib several months
ago. She further noted that hypoglycemia had indeed been
the initial manifestation of her EGIST in 2010, but this
symptom had resolved post-operatively.
During the current admission, initial inpatient evalu-
ation revealed a suppressed insulin (<1uIU/mL), pro-
insulin (<1.4pmol/L), C-peptide (0.4 ng/mL) and β-
hydroxy butyrate (0.4 mg/dL), when the serum blood
glucose was 26 mg/dL. A urine sulfonylurea screen was
negative, and adrenal insufficiency was ruled out following
documentation of a normal cortisol response to cosyntro-
pin stimulation. A repeat CT scan revealed evidence of a
diffuse metastatic disease with innumerable soft tissue
peritoneal nodules of various sizes scattered throughout
the abdomen (Fig. 1a). The largest mass was seen in the
right lower quadrant and was >7 cm in the largest dimen-
sion (Fig. 1b). Given biochemical and imaging findings,
consideration for EGIST-associated NICTH was made.
IGF-I and II levels were assayed and found to be 27 ng/ml
(reference range: 75–263 ng/mL) and 262 ng/ml (refer-
ence range: 47–350 ng/mL), respectively. The ratio of
IGF-II to IGF-I was calculated as 9.7:1.
Fine needle aspiration and core biopsy of the right
lower quadrant mass were performed. H&E staining re-
vealed the typical spindle shaped morphology (Fig. 1c).
Immunostaining for CD117 (Fig. 1d) and Discovered on
GIST-1 (DOG-1) (Fig. 1e) were diffusely positive. Muscle
specific actin (HHF-35), a mesenchymal marker present
in 47% of GIST biopsies, was positive, while immuno-
staining for carcinoma markers were negative (not
shown). Hence, a diagnosis of recurrent metastatic
EGIST was made. Tumor sections were next stained
with an antibody that recognized both big IGF-II and
mature IGF-II (Abcam, Cambridge MA). Consistent
with the patient’s presentation with severe hypoglycemia,
the tumor stained positive for big IGF-II/IGF-II (Fig. 1f ).
Discussion
The true incidence of NICTH is unclear, but has been
estimated to be extremely rare at approximately one per
one million person years [10]. Hypoglycemia is thought
to arise from excessive tumor production of IGF-II or its
precursor high molecular weight “big” IGF-II. Hence the
term “IGFII-oma” is often used to describe these tumors
[1]. Both IGF-I and IGF-II are structurally related to in-
sulin and act at peripheral insulin receptors to mimic in-
sulin action, leading to increased glucose uptake,
suppression of lipolysis, and inhibition of glycogenolysis,
gluconeogenesis, and ketogenesis in the liver [11].
Under normal conditions, the liver produces IGF-II, in a
growth hormone-independent manner, and IGF-II forms
a biologically inactive ternary complex with IGF binding
proteins (IGFBP), the most common of which are IGFBP3
and acid labile subunit (ALS) [12, 13]. Tumor-produced
IGF-II has an equal affinity for IGFBPs compared to IGFI
and II. However, instead of forming an inactive ternary
complex, IGF-II forms smaller binary complexes with
IGFBP. In NICTH, there is an increase in the quantity of
unbound and active IGF-II as well as increased formation
of these active binary complexes, which exhibit increased
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vasculature permeability and significantly increased bio-
availability. As a side mechanism, increased IGF-II in turn
further suppresses hepatic IGFBP production, thus propa-
gating further insulin like activity and creating a vicious
cycle of severe and symptomatic hypoglycemia [12].
NICTH is typically a diagnosis of exclusion, but should
be suspected when hypoglycemia without hyperinsuline-
mia is present. Biochemically, insulin, proinsulin, C-
peptide, growth hormone and β-hydroxybutyrate levels
are low at the time of hypoglycemia, as was observed in
this patient. In contrast, IGF-II or IGF-II precursor levels
are often elevated. Typically an IGF-II:IGF-I ratio of 10:1
is considered pathognomonic, while a normal ratio is
around 3:1 [1, 12]. In our patient, the levels were 9.7:1,
which were quite high, though perhaps not diagnostic.
The range of tumors associated with NICTH is broad.
In recent years, a handful of case reports and case series
have described GIST-associated NICTH [4, 9, 11]. GIST
tumors arise from the gut wall. In rare instances, they
arise outside the GI tract in the omentum, mesentery,
and retroperitoneum and are referred to as EGISTs.
EGISTs share the same histological and immunotypic
features and biological behavior as GISTs [4, 14]. The
diagnosis of GIST/EGIST tumors relies on CD117 (c-
KIT) positivity on immunohistochemical staining, which
remains a highly sensitive and specific marker.
Discovered on GIST-1 (DOG1) protein is another re-
cently discovered tumor marker that has particularly util-
ity in identifying tumors harboring mutations in platelet-
derived growth factor-α (PDGFR-α) [15]. Whereas stain-
ing for both CD117 and DOG1 were observed in this
patient’s tumor, formal mutation analysis was not per-
formed. Surgery remains the mainstay for localized GIST/
EGIST. However, immunotherapy with tyrosine kinase
inhibitors (TKI), especially imatinib, has emerged as a
promising neoadjuvant or alternative therapy. TKIs are
especially useful in surgically unresectable or malignant
tumors, and the advent of TKIs has increased median
survival in such cases by nearly 50% [16, 17].
Besides resection and therapy aimed at shrinking the
underlying tumor, management of NICTH is typically inde-
pendent of its location. A variety of approaches have been
described in literature, including steroids, octreotide and
human recombinant growth hormone (hGH) [18, 19]. Not-
ably, here we describe the use of continuous glucagon infu-
sion as an effective treatment in the acute setting, especially
when intravenous dextrose is ineffective alone. Among
long-term interventions, glucocorticoids have demonstrated
the most efficacy in terms of reversing the biochemical
abnormalities associated with tumor production of IGF-II
[18, 20]. The proposed mechanism of glucocorticoids is
thought to be suppression of IGF-II production by the
tumor and/or its increased sequestration. Indeed published
studies have demonstrated a significant fall in circulating
big IGF-II, accompanied by an increase in serum ALS in re-
sponse to prolonged glucocorticoid use. Interestingly, these
changes were found to be reversible with glucocorticoid
withdrawal. Furthermore, the required dose of steroid ap-
pears to be somewhat individualized and based on both
tumor debulking strategies and the co-administration of
other agents [18, 20]. Table 1 summarizes available pub-
lished studies in which steroids were used either solely or
a b c
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Fig. 1 Imaging and Pathologic Analysis of the Tumor. a-b Abdominal CT scan revealed diffuse intraabdominal metastatic disease. c Hematoxylin
and eosin (H&E) staining of the tumor revealed a spindle cell morphology (40X). Tumor immunostaining revealed the presence of d CD117 (40X);
e DOG-1 (40X); and f IGF-II (20X)
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in conjunction with other therapies in cases of inoperable
NICTH (Table 1). In aggregate, the initial dose of gluco-
corticoid was at least 30 mg or its steroid equivalent dose,
with attempts made to taper therapy based on the mainten-
ance of euglycemia [19–21]. The minimum effective daily
dose in cases employing only steroids was 20 mg once daily
or 5 mg three times a day, with further dose reductions
resulting in relapse of hypoglycemia [18, 20]. The ideal dur-
ation of therapy remains unclear from the literature, with
most studies having variable follow-up.
Our patient continued to have severe hypoglycemia as
an inpatient. This was acutely treated with continuous
infusions of both glucagon and dextrose. Once the diag-
nosis of recurrent NICTH was established, she was suc-
cessfully transitioned to prednisone 40 mg once daily,
and euglycemia was achieved. Since surgical resection
was not a viable option given the extent of her disease,
imatinib was restarted after discussion with oncology
with the aim of decreasing tumor burden. Over the next
few months, she was successfully weaned off all steroids
and repeat imaging demonstrated some shrinkage of the
tumor with TKI therapy.
Conclusion
In summary, NICTH is a rare paraneoplastic phenomenon
that has been described in association with a variety of
neoplasms. The pathophysiology of NICTH arises from
excessive tumor production of both IGF-II and its precur-
sor “big” IGF-II, resulting in an altered IGF-I to IGF-II ra-
tio and insulin-independent stimulation of the insulin
receptor. While cases of GIST associated NICTH have
been reported, to our knowledge, our patient remains dis-
tinctive in having an extremely rare extragastrointestinal
GIST tumor with an even more rare presentation of non-
islet cell tumor hypoglycemia. While definitive treatment
involves tumor resection and/or adjuvant treatment with
TKIs, corticosteroids have been shown to successfully alle-
viate hypoglycemia. The overall consensus from a limited
number of published reports suggests initiating steroids at
a dose of prednisone 30 mg or higher and then tapering
over weeks to months to the smallest dosage required to
maintain euglycemia [18].
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1 Three different phases of study: phase 1 with
prednisone only, phase 2 with hGH only, phase
3 with both.
The lowest effective dose when steroids were
used alone was prednisone 30 mg.
Days (experimental
study)
To assess if combination therapy with low
dose steroid and hGH is effective in inoperable
patients with NICTH.
Perros, et al.
1996 [19]
1 Prednisone 30 mg once daily given with a
combination of hGH and bendrofluazide; steroids
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9 months Case Report
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